ArticleMolecular cancer therapeutics2013

Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.

Mayur A Gadhikar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.